Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis

A. Ishida, M. Handa, Masatoshi Wakui, Shinichiro Okamoto, Mitsuhiro Kamakura, Y. Ikeda

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

BACKGROUND: Platelet transfusion refractoriness remains problematic in the management of patients who have undergone hematopoietic progenitor cell transplantation. Bone marrow transplantation itself is reported to be a relevant factor hampering efficient platelet transfusions. However, a prospective analysis assessing factors affecting platelet transfusion efficacy in the setting of hematopoietic progenitor cell transplantation has yet to be conducted. STUDY DESIGN AND METHODS: To identify factors independently influencing platelet transfusion efficacy after hematopoietic progenitor cell transplantation, a prospective study was performed to determine the effectiveness of platelet transfusions by estimating posttransfusion (16-hour) corrected count increments (CCI) in 42 consecutive patients (26 who received allogeneic transplants and 16 who received autologous transplants) with 439 available platelet transfusions. RESULTS: The mean CCI and percentage of CCI <4500 for all transfusions were 6161.1 ± 7775.2 per μL and 42.1 percent, respectively. Multiple linear regression analyses revealed high total bilirubin, total body irradiation, high serum tacrolimus, and high serum cyclosporin A to be major factors independently predicting a lower CCI. HLA antibodies with restricted specificitY and platelet antibodies were detected transiently in 17 and 14 percent of the patients, respectively. The presence of these antibodies was not, however, associated with a poor response to platelet transfusions. CONCLUSION: Platelet transfusion efficacy in hematopoietic progenitor cell transplant recipients is markedly influenced by clinical factors specific to the procedure as well as those already recognized in other settings. Alloimmu- nization is not, however, a major factor associated with a poor response to platelet transfusions after this procedure.

Original languageEnglish
Pages (from-to)839-847
Number of pages9
JournalTransfusion
Volume38
Issue number9
Publication statusPublished - 1998 Sep

Fingerprint

Platelet Transfusion
Cell Transplantation
Hematopoietic Stem Cells
Blood Platelets
Transplants
Antibody Specificity
Antibodies
Whole-Body Irradiation
Autografts
Tacrolimus
Serum
Bone Marrow Transplantation
Bilirubin
Cyclosporine
Statistical Factor Analysis
Linear Models
Regression Analysis
Prospective Studies

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis. / Ishida, A.; Handa, M.; Wakui, Masatoshi; Okamoto, Shinichiro; Kamakura, Mitsuhiro; Ikeda, Y.

In: Transfusion, Vol. 38, No. 9, 09.1998, p. 839-847.

Research output: Contribution to journalArticle

@article{a7b0dfe1e6e84c1e8178e9d59bebe84e,
title = "Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis",
abstract = "BACKGROUND: Platelet transfusion refractoriness remains problematic in the management of patients who have undergone hematopoietic progenitor cell transplantation. Bone marrow transplantation itself is reported to be a relevant factor hampering efficient platelet transfusions. However, a prospective analysis assessing factors affecting platelet transfusion efficacy in the setting of hematopoietic progenitor cell transplantation has yet to be conducted. STUDY DESIGN AND METHODS: To identify factors independently influencing platelet transfusion efficacy after hematopoietic progenitor cell transplantation, a prospective study was performed to determine the effectiveness of platelet transfusions by estimating posttransfusion (16-hour) corrected count increments (CCI) in 42 consecutive patients (26 who received allogeneic transplants and 16 who received autologous transplants) with 439 available platelet transfusions. RESULTS: The mean CCI and percentage of CCI <4500 for all transfusions were 6161.1 ± 7775.2 per μL and 42.1 percent, respectively. Multiple linear regression analyses revealed high total bilirubin, total body irradiation, high serum tacrolimus, and high serum cyclosporin A to be major factors independently predicting a lower CCI. HLA antibodies with restricted specificitY and platelet antibodies were detected transiently in 17 and 14 percent of the patients, respectively. The presence of these antibodies was not, however, associated with a poor response to platelet transfusions. CONCLUSION: Platelet transfusion efficacy in hematopoietic progenitor cell transplant recipients is markedly influenced by clinical factors specific to the procedure as well as those already recognized in other settings. Alloimmu- nization is not, however, a major factor associated with a poor response to platelet transfusions after this procedure.",
author = "A. Ishida and M. Handa and Masatoshi Wakui and Shinichiro Okamoto and Mitsuhiro Kamakura and Y. Ikeda",
year = "1998",
month = "9",
language = "English",
volume = "38",
pages = "839--847",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation - A prospective analysis

AU - Ishida, A.

AU - Handa, M.

AU - Wakui, Masatoshi

AU - Okamoto, Shinichiro

AU - Kamakura, Mitsuhiro

AU - Ikeda, Y.

PY - 1998/9

Y1 - 1998/9

N2 - BACKGROUND: Platelet transfusion refractoriness remains problematic in the management of patients who have undergone hematopoietic progenitor cell transplantation. Bone marrow transplantation itself is reported to be a relevant factor hampering efficient platelet transfusions. However, a prospective analysis assessing factors affecting platelet transfusion efficacy in the setting of hematopoietic progenitor cell transplantation has yet to be conducted. STUDY DESIGN AND METHODS: To identify factors independently influencing platelet transfusion efficacy after hematopoietic progenitor cell transplantation, a prospective study was performed to determine the effectiveness of platelet transfusions by estimating posttransfusion (16-hour) corrected count increments (CCI) in 42 consecutive patients (26 who received allogeneic transplants and 16 who received autologous transplants) with 439 available platelet transfusions. RESULTS: The mean CCI and percentage of CCI <4500 for all transfusions were 6161.1 ± 7775.2 per μL and 42.1 percent, respectively. Multiple linear regression analyses revealed high total bilirubin, total body irradiation, high serum tacrolimus, and high serum cyclosporin A to be major factors independently predicting a lower CCI. HLA antibodies with restricted specificitY and platelet antibodies were detected transiently in 17 and 14 percent of the patients, respectively. The presence of these antibodies was not, however, associated with a poor response to platelet transfusions. CONCLUSION: Platelet transfusion efficacy in hematopoietic progenitor cell transplant recipients is markedly influenced by clinical factors specific to the procedure as well as those already recognized in other settings. Alloimmu- nization is not, however, a major factor associated with a poor response to platelet transfusions after this procedure.

AB - BACKGROUND: Platelet transfusion refractoriness remains problematic in the management of patients who have undergone hematopoietic progenitor cell transplantation. Bone marrow transplantation itself is reported to be a relevant factor hampering efficient platelet transfusions. However, a prospective analysis assessing factors affecting platelet transfusion efficacy in the setting of hematopoietic progenitor cell transplantation has yet to be conducted. STUDY DESIGN AND METHODS: To identify factors independently influencing platelet transfusion efficacy after hematopoietic progenitor cell transplantation, a prospective study was performed to determine the effectiveness of platelet transfusions by estimating posttransfusion (16-hour) corrected count increments (CCI) in 42 consecutive patients (26 who received allogeneic transplants and 16 who received autologous transplants) with 439 available platelet transfusions. RESULTS: The mean CCI and percentage of CCI <4500 for all transfusions were 6161.1 ± 7775.2 per μL and 42.1 percent, respectively. Multiple linear regression analyses revealed high total bilirubin, total body irradiation, high serum tacrolimus, and high serum cyclosporin A to be major factors independently predicting a lower CCI. HLA antibodies with restricted specificitY and platelet antibodies were detected transiently in 17 and 14 percent of the patients, respectively. The presence of these antibodies was not, however, associated with a poor response to platelet transfusions. CONCLUSION: Platelet transfusion efficacy in hematopoietic progenitor cell transplant recipients is markedly influenced by clinical factors specific to the procedure as well as those already recognized in other settings. Alloimmu- nization is not, however, a major factor associated with a poor response to platelet transfusions after this procedure.

UR - http://www.scopus.com/inward/record.url?scp=0031686502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031686502&partnerID=8YFLogxK

M3 - Article

C2 - 9738624

AN - SCOPUS:0031686502

VL - 38

SP - 839

EP - 847

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 9

ER -